Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) by Jones, T. Hugh et al.
Testosterone Replacement in
Hypogonadal Men With Type 2
Diabetes and/or Metabolic Syndrome
(the TIMES2 Study)
T. HUGH JONES, MD, FRCP
1,2
STEFAN ARVER, MD
3
HERMANN M. BEHRE, MD
4
JACQUES BUVAT, MD
5
ERIC MEULEMAN, MD
6
IGNACIO MONCADA, MD
7
ANTONIO MARTIN MORALES, MD
8
MAURIZIO VOLTERRANI, MD, FCCP
9
ANN YELLOWLEES, CSTAT
10
JULIAN D. HOWELL, MB, BS, FRCS, MFPM
11
KEVIN S. CHANNER, MD, FRCP
12
TIMES2 INVESTIGATORS*
OBJECTIVE—This study evaluated the effects of testosterone replacement therapy (TRT) on
insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2
diabetes and/or metabolic syndrome (MetS).
RESEARCH DESIGN AND METHODS—The efﬁcacy, safety, and tolerability of a novel
transdermal 2% testosterone gel was evaluated over 12 months in 220 hypogonadal men with
type 2 diabetes and/or MetS in a multicenter, prospective, randomized, double-blind, placebo-
controlled study. The primary outcome was mean change from baseline in homeostasis model
assessment of insulin resistance (HOMA-IR). Secondary outcomes were measures of body com-
position, glycemic control, lipids, and sexual function. Efﬁcacy results focused primarily on
months 026 (phase 1; no changes in medication allowed). Medication changes were allowed
in phase 2 (months 6212).
RESULTS—TRT reduced HOMA-IR in the overall population by 15.2% at 6 months (P =
0.018) and 16.4% at 12 months (P = 0.006). In type 2 diabetic patients, glycemic control was
signiﬁcantly better in the TRT group than the placebo group at month 9 (HbA1c:t r e a t m e n t
difference, 20.446%; P = 0.035). Improvements in total and LDL cholesterol, lipoprotein a
(Lpa), body composition, libido, and sexual function occurred in selected patient groups. There
were no signiﬁcant differences between groups in the frequencies of adverse events (AEs) or
serious AEs. The majority of AEs (.95%) were mild or moderate.
CONCLUSIONS—Over a 6-month period, transdermal TRT was associated with beneﬁcial
effects on insulin resistance, total and LDL-cholesterol, Lpa, and sexual health in hypogonadal
men with type 2 diabetes and/or MetS.
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L
owserumtestosteroneiscommonin
men with type 2 diabetes and/or
metabolic syndrome (MetS) and nu-
merous studies have reported an associ-
ationbetweentestosteronedeﬁciencyand
visceral obesity, insulin resistance (IR)
and dyslipidemia (1–4). In men with
type 2 diabetes, low testosterone is asso-
ciated with a high prevalence of symp-
tomatic hypogonadism (3), frequently
due to hypogonadotrophic hypogonad-
ism (5).
Small studies have demonstrated that
testosterone replacement therapy (TRT)
in hypogonadal men with and without
type 2 diabetes is associated with reduc-
tions in IR, waist circumference, choles-
terol, glycated hemoglobin (HbA1c), and
fasting plasma glucose (FPG) concentra-
tions (6–9). Conversely, withdrawal of
TRT in hypogonadal men leads to de-
creased insulin sensitivity (10). Further-
more, androgen suppression therapy for
prostate cancer can result in alterations of
individual cardiovascular risk factors and
increases the occurrence of incident dia-
betes, myocardial infarction and sudden
cardiac death (11,12). Epidemiologic
studies have reported that low testoster-
one in men is associated with increased
all-cause and cardiovascular mortality
(13).
The TIMES2 (Testosterone replace-
ment In hypogonadal men with either
MEtabolic Syndrome or type 2 diabetes)
study investigated the effects of transder-
mal TRT on IR, selected cardiovascular
risk factors, and symptoms in hypogona-
dalmenwithMetSand/ortype2diabetes.
The safety and tolerability of a novel,
metered-dose, transdermal 2% testoster-
one gel were also examined.
RESEARCH DESIGN AND
METHODS—This 12-month, pro-
spective, randomized, double-blind,
placebo-controlled, multicenter study was
conducted at 36 outpatient centers in
Belgium, France, Germany, Italy, the
Netherlands, Spain, Sweden, and the
U.K. between February 2006 and March
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ORIGINAL ARTICLE2007. The study was conducted in accor-
dance with the revised guidelines of the
World Medical Association Declaration of
Helsinki, the International Conference on
Harmonization Standard Operating Pro-
cedures, and local laws and regulatory
requirements. The study protocol was
approved by independent ethics commit-
tees for each center. Participants provided
written informed consent.
Men aged $40 years were eligible to
enter the study if they had conﬁrmed
hypogonadism (early morning [08002
1000 h] total testosterone [TT] #11
nmol/L or free testosterone #255 pmol/L
on two occasions $1 week apart), with at
least two symptoms of hypogonadism
(14) and fulﬁlled criteria for type 2 diabe-
tes (15) and/or MetS (16) (Supplementary
Data). Erectile dysfunction was not an in-
clusion criterion.
ExclusioncriteriaincludedTRTwithin
6 months of randomization, hormone-
modulating therapies or topical/systemic
glucocorticoids within 3 months of ran-
domization,orinsulintherapy;ahistoryof/
current prostate or breast cancer; abnor-
mal digital rectal examination suggestive
of prostate carcinoma; severe symptom-
atic benign prostatic hyperplasia or ele-
vated age-speciﬁc prostate-speciﬁc antigen
(PSA) (17).ForPSAlevelsandotherexclu-
sion criteria see the Supplementary Data.
Concomitant medications (oral antidia-
betic drugs [OADs], lipid-lowering thera-
pies, antihypertensives) were continued if
doses had remained stable for $3 months
before randomization. The ﬁrst 6 months
of the study, during which no therapy
changes were permitted unless the investi-
gator deemed it necessary for good clinical
practice, was designated Phase 1. The sec-
ond 6-month period, when changes in
medication were allowed, was designated
Phase 2.
Subjects were randomized (1:1) to
receive either 3 g metered-dose 2% tes-
tosterone gel (60 mg testosterone, Tos-
tran [also known as Fortigel, Tostrex,
Itnogen, Foresta; ProStrakan, Galashiels,
Scotland, U.K.]) or placebo gel once daily
andstratiﬁedtotreatmentarmsaccording
to the presence of MetS only and type 2
diabetes with or without MetS. All indi-
viduals involved in monitoring, data
management, or other study aspects
were blinded to treatment.
Treatment was applied daily
(070021000 h) to clean, dry, intact skin
on the thighs or abdomen. Blood samples
were taken 2 h after application. TT was
measured at 2, 4, and 12 weeks with dose
adjustments made as follows: TT .52
nmol/L, TRT dose reduced to 40 mg/day;
TT ,17 nmol/L, dose increased to 80
mg/day. Dummy dose changes were per-
formed in the placebo group to maintain
blinding.
All laboratory assessments (Sup-
plementary Data) were performed cen-
trally by Pivotal Laboratories Ltd., York,
U.K. Measurements were taken at base-
line,thenevery3monthsforHbA1c,PSA,
lipids (total cholesterol [TC], HDL cho-
lesterol, LDL cholesterol, triglycerides,
lipoprotein a [Lpa]), hematology, bio-
chemistry,testosterone,FPG(no9-month
measurement) and insulin (mean of three
samples at 5-min intervals, no 9-month
measurement). Free testosterone was
calculated from TT, albumin, and sex
hormone binding globulin, using the Ver-
meulen equation (18). Waist circumfer-
ence, BMI, body composition (TANITA
BF-300 body fat analyzer; TANITA Cor-
poration, Tokyo, Japan), Aging Males
Symptoms(AMS) score (19), and Interna-
tional Index of Erectile Function (IIEF)
(20) were assessed at baseline, 6, and 12
months. Adverse events (AEs) were elic-
itedfromthepatientateachvisitbyanon-
leading question.
Statistical analysis
The primary end point was the difference
between treatment groups in homeostasis
modelassessment(HOMA)-IRfrombase-
line to months 6 and 12. Secondary end
points were changes from baseline in
HbA1c, fasting insulin, FPG, lipid param-
eters, body composition, BMI, waist cir-
cumference, AMS and IIEF scores, AEs,
and other safety parameters. HOMA of
b-cell function (HOMA-B) was deter-
mined post hoc.
The safety population comprised all
randomized patients who received $1
dose of study medication. The primary
analysis of all end points was based on
the intention-to-treat (ITT) population
(all randomized patients). Two other
populations were also studied: the per-
protocol (PP) population (randomized
patients who received $1d o s eo fs t u d y
medication with no protocol violations
during the ﬁrst 6 months of the study)
and the modiﬁed PP (mPP) population.
This latter population was established
post hoc because the PP population was
substantially reduced in size after exclu-
sion of patients who took unauthorized
concomitant medications from the ITT
population (Supplementary Data). Pa-
tients’ eligibility for inclusion in the mPP
populationwasassessedonacase-by-case
basis for each end point. Inclusion was
allowed if there were no changes in drugs
during the ﬁrst 6 months that affected the
end point in question. These were OADs
and antiobesity drugs for HOMA-IR (n =
130);OADs,antiobesitydrugs,b-blockers,
and diuretics for body composition (n =
147); lipid-lowering drugs, b-blockers,
and a-blockers for lipid proﬁle (n = 139);
OADs, antiobesity drugs, b-blockers, and
diuretics for HbA1c and FPG (n = 140);
phosphodiesterase-5 inhibitors and
b-blockers for AMS (n = 152) and IIEF
(n = 154); and antihypertensive drugs for
blood pressure (n =1 4 0 ) .
The study was designed to have a
power of 95% to detect a mean difference
in HOMA-IR change from baseline be-
tween TRT and placebo of 0.82 (SD 1.7)
at 6 months. After completion of an
interim analysis in 63 patients, the study
power was revised to 80%, giving a ﬁnal
target completer sample of 136 patients.
All statistical analyses (Chiltern Interna-
tionalLtd;Quantics,NewtownStBoswells,
U.K.) were conducted using SAS version
8.2 (SAS Institute, Cary, NC) or later.
Descriptive statistics were calculated for
continuous variables, with 95% CI, SD,
and P values. For comparison of efﬁcacy
outcomes between treatment groups
(treatment difference [TD]), an ANCOVA
model was applied, with disease category
as a covariate (MetS and type 2 diabetes;
MetSonly;type2diabetesonly).P,0.05
was considered statistically signiﬁcant
for all analyses. No adjustment was
made for multiple testing as all second-
ary end points were regarded as explor-
atory. For the primary end point and
HOMA-B, a log transformation was ap-
plied for the ANCOVA and a last obser-
vation carried forward approach was
used.Unlessotherwisestated,allefﬁcacy
data were analyzed in the ITT popula-
tion, all safety data were analyzed in the
safety population, and all results are
quoted as mean 6 SD.
RESULTS—Of 518 patients screened,
220 were randomized (testosterone n =
108;placebon=112)andreceivedatleast
one dose of study drug (ITT and safety
populations). Baseline demographic and
clinical characteristics were comparable
between groups (Table 1). Phase 1 was
completed by 157 patients (71%), and
Phases 1 and 2 were completed by 118
(54%) (Supplementary Fig. A1). Reasons
for early withdrawal included protocol
violation (n = 28), withdrawal of consent
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up (n = 9). Protocol was violated by 125
patients, giving a PP population of 95.
Hypogonadotrophic or secondary hypo-
gonadism, deﬁnedaslowornormallutei-
nizing hormone, occurred in 82% of
subjects whereas 18% demonstrated pri-
mary hypogonadism (Supplementary
Table A1). The majority of subjects
(80%) had MetS at baseline, and 62%
had type 2 diabetes. MetS and type 2 di-
abeteswerebothpresentin44and40%of
theTRTandplacebogroups,respectively.
Baseline serum TT values were 9.2 6 2.6
nmol/L(TRT)and 9.56 3.3 nmol/L(pla-
cebo). The majority of subjects (62.6%)
qualiﬁedforstudyentry,meetingbothTT
and free testosterone criteria. Of the sub-
jects, 12.3and 23.7%qualiﬁed on the ba-
sis of TT ,11 nmol/L or free testosterone
,255 pmol/L, respectively.
Efﬁcacy: Phase 1
At the end of Phase 1 (6 months), serum
TT values in the ITT population had
increased by 19.0 6 22.1 nmol/L with
TRT versus 0.1 6 2.9 nmol/L with pla-
cebo (P , 0.001).
TRT reduced HOMA-IR by 15.2%
(95% CI 3–26; P = 0.018) compared with
placebo at 6 months (Fig. 1). Type 2 di-
abetic patients demonstrated mean re-
ductions in HOMA-IR of 16.0% (0–29;
P = 0.049) compared with placebo. The
differencebetweentreatmentsintheMetS
patients approached signiﬁcance (TD
13.3% [21t o2 6 ] ;P = 0.069) (Fig. 1).
PosthocanalysesofHOMA-IRinpatients
without type 2 diabetes only, showed no
difference between treatment groups
(Supplementary Table A2). There were
no signiﬁcant differences between treat-
ments in the overall population or the dis-
ease subgroups in HbA1c (Fig. 1), fasting
seruminsulin,FPG,orHOMA-B(Table2).
TRT had a number of beneﬁcial
effects on lipid proﬁle. In the MetS sub-
group, TRT was associated with signiﬁ-
cantly greater reductions from baseline in
plasma levels of Lpa (TD 20.31 mmol/L
[95% CI 20.543 to 20.082]; P = 0.008),
TC (TD 20.336 mmol/L [20.558 to
20.114]; P = 0.003) and LDL cholesterol
(TD 20.210 mmol/L [9520.374 to
20.047]; P = 0.012) than placebo (Table
2). TRT also reduced Lpa in the overall
ITT population (TD 20.235 mmol/L
[20.431 to 20.039]; P = 0.019). HDL
cholesterol decreased from baseline sig-
niﬁcantly more with TRT than placebo
in all three analysis groups (total popula-
tion [TD 20.049 mmol/L (20.094 to
20.004); P = 0.032], MetS [TD 20.058
mmol/L (20.105 to 20.011); P = 0.016],
type 2 diabetes [TD 20.062 mmol/L
(20.123 to 20.002); P = 0.043]). There
were no signiﬁcant effects of TRT on tri-
glycerides,abdominalobesity,percentage
body fat, BMI, or waist circumference.
In the overall ITT population, TRT
was associated with signiﬁcantly greater
increases from baseline in total IIEF score
(TD 4.868 [95% CI 0.644–9.092]; P =
0.024) and in the sexual desire domain
(TD 0.800 [0.271–1.329]; P = 0.003)
(Table 2). Treatment had no signiﬁcant
effectonerectilefunction,orgasmicfunc-
tion, or overall sexual satisfaction, al-
though these three measures did show a
consistent trend for greater improvement
with TRT versus placebo. Change in
AMS score was similar in both treatment
groups.
Data for secondary end points in the
mPP and PP populations are shown in
SupplementaryTablesA3andA4,respec-
tively. The smallsize of the PP population
negated statistical power and the differ-
ence between groups in HOMA-IR re-
duction was not statistically signiﬁcant
Table 1—Baseline characteristics (safety population)
Testosterone Placebo Total
n 108 112 220
Age (years) 59.9 6 9.1 (37277) 59.9 6 9.4 (39288) 59.9 6 9.3 (37288)
Race
Caucasian 105 (97) 110 (98) 215 (98)
Asian 3 (3) 0 3 (1)
Afro-Caribbean 0 1 (1) 1 (0.5)
O t h e r 0 1( 1 ) 1( 0 . 5 )
Total serum testosterone (nmol/L) 9.2 6 2.6 (3.8220.1) 9.5 6 3.3 (2.2220.6) 9.4 6 3.0 (2.2220.6)
Free testosterone (pmol) 198.0 6 49.3 (422319) 202.4 6 62.1 (352364) 200.3 6 56.1 (352364)
Type 2 diabetes 68 (6) 69 (62) 137 (62)
MetS 88 (82) 88 (79) 176 (80)
Insulin resistance (HOMA-IR index) 5.9 6 3.8 (1220) 4.9 6 3.3 (1221) 5.4 6 3.6 (1221)
Hematocrit (L/L) 0.43 6 0.04 (0.3420.54) 0.43 6 0.04 (0.3320.51) 0.43 6 0.04 (0.3320.54)
Hemoglobin (g/dL) 14.9 6 1.5 (11.0218.6) 14.9 6 1.3 (11.4218.0) 14.9 6 1.4 (11.0218.6)
PSA (mg/L) 1.6 6 1.8 (0.21213.60) 1.2 6 1.2 (0.2026.38) 1.4 6 1.5 (0.20213.60)
FSH* (IU/L) 12.3 6 13.4 (1.2263.6) 12.5 6 15.7 (1.2278.9) 12.4 6 14.5 (1.2278.9)
FSH*
Low 0 0 0
Normal 77 (71) 79 (71) 156 (71)
High 31 (29) 33 (29) 64 (29)
LH* (IU/L) 5.7 6 5.7 (0.9234.3) 5.3 6 5.4 (0.6236.1) 5.5 6 5.5 (0.6236.1)
LH*
L o w 0 2( 2 ) 2( 1 )
Normal 86 (80) 92 (82) 178 (81)
High 22 (20) 18 (16) 40 (18)
Data are mean 6 SD (range) or n (%) unless otherwise indicated. FSH, follicle stimulating hormone; LH, luteinizing hormone. *Screening values (not measured at
baseline). Normal ranges: 0.7 IU/L # FSH # 11.1 IU/L; 0.8 IU/L # LH # 7.6 IU/L.
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Testosterone therapy in hypogonadal men(TRT 20.92 6 2.454, placebo 20.06 6
2.451; P = 0.17). However, reductions
from baseline in Lpa, TC, LDL choles-
terol, and HDL cholesterol were signiﬁ-
cantly greater in the TRT group than in
the placebo group (overall PP cohort). In
theexploratorymPPpopulation,TRTwas
associated with signiﬁcant reductions
from baseline in percentage body fat,
Lpa, TC, and LDL cholesterol in all pa-
tients and in the MetS subgroup
(Supplementary TableA3).Thetype 2 di-
abetes subgroup showed signiﬁcant re-
ductions in Lpa and percentage body fat
with TRT (Supplementary Table A3).
There were no signiﬁcant between-group
differencesinHDLcholesterolinthemPP
population (Supplementary Table A3).
No other end points were signiﬁcantly
different between treatment groups in
the PP or mPP populations.
Figure 1—Mean (95% CI) percentage change from baseline in HOMA-IR (ITT population, last observation carried forward) and change from
baseline in HbA1c(ITT population, study completers) among all patients (A and D), patients with type 2 diabetes (B andE),and patients with MetS
(C and F). P values reported for comparisons between groups.
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Jones and AssociatesTable 2—Mean values for primary and secondary end points at baseline and months 6 and 12 (ITT population, last observation
carried forward)
All patients MetS patients Type 2 diabetic patients
Testosterone Placebo Testosterone Placebo Testosterone Placebo
Glucose metabolism
Fasting serum insulin (pmol/L)
Baseline 151.68 6 153.26 137.65 6 147.46 162.17 6 166.29 153.76 6 163.02 145.08 6 158.55 126.19 6 109.17
n 1 0 2 1 0 58 28 16 46 5
Phase 1: Month 6 124.59 6 98.65 128.20 6 99.76 125.08 6 86.89 135.50 6 104.45 121.61 6 102.01 136.40 6 117.44
n 1 0 1 1 0 18 38 06 56 3
Phase 2: Month 12 134.25 6 108.57 126.89 6 94.31 135.50 6 100.92 131.33 6 98.47 130.91 6 113.99 131.96 6 104.30
n 1 0 3 1 0 18 58 06 56 3
FPG (mmol/L)
Baseline 7.94 6 2.99 7.59 6 2.62 7.60 6 2.41 7.60 6 2.71 9.05 6 3.18 8.49 6 2.84
n 1 0 4 1 0 78 48 36 76 7
Phase 1: Month 6 7.84 6 3.03 7.99 6 2.86 7.67 6 2.82 7.88 6 2.99 8.91 6 3.31 9.09 6 2.97
n 1 0 2 1 0 18 48 06 56 3
Phase 2: Month 12 7.97 6 3.45 8.14 6 3.19 7.74 6 3.25 8.05 6 3.41 9.18 6 3.75 9.35 6 3.46
n 1 0 2 1 0 18 48 06 56 3
HOMA-B†
Baseline 104.8 6 77.5 99.9 6 75.8 110.5 6 78.3 104.7 6 74.7 83.3 6 67.0 84.1 6 74.0
n 9 9 1 0 58 08 16 46 6
Phase 1: Month 6 100.7 6 78.9 98.3 6 72.7 103.9 6 79.4 106.0 6 74.9 79.4 6 66.0 75.3 6 58.2
n 1 0 5 1 0 88 68 46 76 7
Phase 2: Month 12 102.0 6 79.5 99.4 6 70.8 105.1 6 80.1 105.4 6 70.2 79.1 6 65.4 79.3 6 66.5
n 1 0 5 1 0 98 68 56 76 8
Lipid parameters
Lpa (mmol/L)
Baseline 1.44 6 1.56 1.40 6 1.17 1.50 6 1.64 1.42 6 1.21 1.36 6 1.36 1.37 6 1.28
n 98* 102 81** 79 62 64
Phase 1: Month 6 1.22 6 1.19 1.59 6 1.80 1.22 6 1.20 1.49 6 1.65 1.20 6 1.16 1.61 6 2.15
n 96* 98 80** 79 62 60
Phase 2: Month 9 1.39 6 1.39 1.90 6 1.94 1.37 6 1.43 1.77 6 1.58 1.51 6 1.52 1.96 6 2.34
n 51* 56 43 44 35 35
Phase 2: Month 12 1.26 6 1.22 1.62 6 1.82 1.26 6 1.24 1.49 6 1.38 1.29 6 1.26 1.65 6 2.19
n 99 100 83** 80 63 61
TC (mmol/L)
Baseline 4.65 6 1.18 4.87 6 1.11 4.79 6 1.22 4.98 6 1.09 4.51 6 1.17 4.55 6 1.01
n 1 0 6 1 0 88 68 46 76 7
Phase 1: Month 6 4.52 6 1.11 4.89 6 1.13 4.56 6 1.11 5.05 6 1.13 4.44 6 1.12 4.57 6 0.97
n 103 102 85** 81 66 63
Phase 2: Month 9 4.55 6 1.24 4.80 6 1.12 4.61 6 1.24 4.95 6 1.10 4.32 6 1.14 4.59 6 1.13
n 62 65 54 52 42 39
Phase 2: Month 12 4.49 6 1.16 4.77 6 1.07 4.52 6 1.17 4.88 6 1.05 4.31 6 1.05 4.52 6 0.95
n 1 0 4 1 0 28 68 16 66 3
LDL cholesterol (mmol/L)
Baseline 2.78 6 0.99 2.89 6 0.96 2.89 6 1.02 2.98 6 0.95 2.61 6 0.91 2.61 6 0.82
n 1 0 6 1 0 88 68 46 76 7
Phase 1: Month 6 2.65 6 0.91 2.85 6 0.91 2.70 6 0.95 2.99 6 0.93 2.60 6 0.85 2.55 6 0.70
n 103 102 85* 81 66 63
Phase 2: Month 9 2.67 6 1.01 2.77 6 0.88 2.70 6 1.01 2.90 6 0.90 2.53 6 0.93 2.51 6 0.77
n 62 65 54 52 42 39
Phase 2: Month 12 2.59 6 0.91 2.75 6 0.89 2.62 6 0.93 2.85 6 0.91 2.49 6 0.82 2.50 6 0.70
n 1 0 4 1 0 28 68 16 66 3
HDL cholesterol (mmol/L)
Baseline 1.19 6 0.30 1.23 6 0.28 1.21 6 0.31 1.21 6 0.26 1.16 6 0.31 1.23 6 0.29
n 1 0 6 1 0 88 68 46 76 7
Phase 1: Month 6 1.12 6 0.26* 1.21 6 0.25 1.12 6 0.24 1.20 6 0.24 1.09 6 0.27 1.21 6 0.26
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All patients MetS patients Type 2 diabetic patients
Testosterone Placebo Testosterone Placebo Testosterone Placebo
n 103 102 85* 81 66* 63
Phase 2: Month 9 1.14 6 0.31 1.20 6 0.27 1.14 6 0.28 1.18 6 0.27 1.12 6 0.33 1.20 6 0.27
n 62 65 54* 52 42 39
Phase 2: Month 12 1.14 6 0.30 1.21 6 0.26 1.14 6 0.28 1.20 6 0.25 1.09 6 0.30 1.21 6 0.27
n 1 0 4 1 0 28 68 16 66 3
Triglycerides (mmol/L)
Baseline 1.92 6 1.36 2.10 6 1.44 1.94 6 1.42 2.21 6 1.52 2.06 6 1.58 2.05 6 1.30
n 1 0 6 1 0 88 68 46 76 7
Phase 1: Month 6 1.93 6 1.23 2.04 6 1.28 1.92 6 1.05 2.10 6 1.34 1.98 6 1.31 2.07 6 1.30
n 1 0 3 1 0 28 58 16 66 3
Phase 2: Month 9 2.00 6 1.21 2.23 6 1.71 2.07 6 1.26 2.29 6 1.76 1.91 6 0.98 2.36 6 1.99
n 62 65 54 52 42 39
Phase 2: Month 12 1.90 6 1.15 2.14 6 1.49 1.91 6 1.06 2.16 6 1.54 1.90 6 1.17 2.19 6 1.49
n 1 0 4 1 0 28 68 16 66 3
Abdominal obesity and body composition
Body fat (%)
Baseline 33.60 6 6.54 32.24 6 6.33 33.99 6 6.69 32.37 6 6.17 33.58 6 5.43 32.54 6 6.55
n 1 0 8 1 1 28 88 86 86 9
Phase 1: Month 6 33.01 6 6.83 32.31 6 5.77 33.31 6 6.82 32.43 6 5.59 32.86 6 5.92 32.33 6 5.88
n 94 98 78 78 61 62
Phase 2: Month 12 32.81 6 7.08 32.63 6 5.57 33.08 6 7.18 32.66 6 5.51 32.69 6 6.44 32.68 6 5.71
n 100 98 83 78 63 62
BMI (kg/m
2)
Baseline 32.87 6 6.58 31.29 6 5.44 33.27 6 6.80 31.63 6 5.07 32.76 6 6.12 31.56 6 5.87
n 1 0 8 1 1 28 88 86 86 9
Phase 1: Month 6 33.07 6 6.96 31.45 6 5.26 33.28 6 7.28 31.67 6 5.03 33.16 6 6.35 31.70 6 5.55
n 97 99 80 79 62 62
Phase 2: Month 12 32.90 6 7.01 31.43 6 5.27 33.17 6 7.35 31.53 6 5.07 32.92 6 6.52 31.73 6 5.57
n 102 99 84 79 64 62
Waist circumference (cm)
Baseline 112.7 6 13.22 110.1 6 13.77 113.3 6 13.43 110.8 6 12.65 112.7 6 13.35 111.7 6 15.23
n 1 0 8 1 1 28 88 86 86 9
Phase 1: Month 6 111.9 6 13.64 110.2 6 13.36 112.0 6 13.62 110.3 6 12.02 113.1 6 13.57 111.8 6 14.46
n 96 99 80 79 61 62
Phase 2: Month 12 111.6 6 13.89 110.6 6 13.96 112.0 6 13.92 110.8 6 12.52 111.9 6 13.79 112.4 6 15.52
n 100 99 83 79 63* 62
Blood pressure
Systolic blood pressure (mmHg)
Baseline 138.6 6 17.30 136.7 6 17.12 ————
n 108 112
Phase 2: Month 12 138.7 6 15.15 134.9 6 16.49 ————
n 50 58
Diastolic blood pressure (mmHg)
Baseline 82.5 6 10.23 81.6 6 9.50
n 108 112
Phase 2: Month 12 82.8 6 9.72 80.3 6 9.80 ————
n 50 58
Sexual dysfunction
IIEF total score
Baseline 32.4 6 18.47 32.8 6 21.24 ————
n 94 98
Phase 1: Month 6 41.3 6 19.97 39.3 6 22.12 ————
n 82* 81
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At the end of Phase 2 (12 months), serum
TT values in the ITT population were
signiﬁcantly higher following TRT
(19.5 6 17.0 nmol/L) versus placebo
(20.6 6 3.3 nmol/L) (P , 0.001).
Changes in concomitant medications
were allowed in Phase 2. Efﬁcacy results
are therefore not presented for this phase
except for HOMA-IR (the primary end
point) and sexual function, a measure of
hypogonadism. In the total ITT popula-
tion, HOMA-IR was signiﬁcantly im-
proved with TRT versus placebo at 12
months (TD 16.4% [95% CI 5–26]; P =
0.006).
Exploratory analysis of the type 2
diabetes mPP subgroup showed HbA1c
decreased slightly by month 9 with TRT
but increasedwith placebo,creating adif-
ference of 20.58% that was signiﬁcant
(P =0.005).Thistrendcontinuednonsig-
niﬁcantly at 12 months (20.49%, P =
0.066).
There was a signiﬁcant improvement
in IIEF total score and sexual desire and
intercourse satisfaction domain scores in
Table 2—Continued
All patients MetS patients Type 2 diabetic patients
Testosterone Placebo Testosterone Placebo Testosterone Placebo
Phase 2: Month 12 40.9 6 20.34 37.3 6 22.08 ————
n 88* 88
Erectile function domain score
Baseline 12.0 6 9.07 11.9 6 10.02
n 101 103
Phase 1: Month 6 15.6 6 9.53 15.1 6 10.49 ————
n 84 89
Phase 2: Month 12 15.2 6 9.71 14.4 6 10.42 ————
n 90 93
Orgasmic function domain score
Baseline 4.6 6 3.80 4.7 6 4.20 ———
n 105 107
Phase 1: Month 6 5.9 6 3.89 5.8 6 4.18 ————
n 88 90
Phase 2: Month 12 5.5 6 3.91 5.3 6 4.23 ————
n 95 93
Sexual desire domain score
Baseline 5.3 6 2.13 5.6 6 2.47 ———
n 105 106
Phase 1: Month 6 6.5 6 2.27 5.9 6 2.38 ————
n 89** 91
Phase 2: Month 12 6.3 6 2.21 5.8 6 2.55 ————
n 94** 95
Intercourse satisfaction domain score
Baseline 4.7 6 4.58 4.7 6 4.84 ————
n 106 108
Phase 1: Month 6 6.2 6 4.95 6.3 6 4.99 ————
n 88 91
Phase 2: Month 12 6.4 6 5.01 5.7 6 4.89 ————
n 94* 92
Overall sexual satisfaction domain score
Baseline 4.7 6 2.46 4.8 6 2.68 ————
n 96 99
Phase 1: Month 6 6.0 6 2.62 5.7 6 2.81 ————
n 85 89
Phase 2: Month 12 5.9 6 2.70 5.5 6 2.73 ————
n 91 94
AMS total score
Baseline 40.6 6 11.44 39.9 6 11.46 ————
n 88 96
Phase 1: Month 6 37.1 6 11.72 36.1 6 10.60 ————
n 80 86
Phase 2: Month 12 36.4 6 11.16 37.8 6 11.57 ————
n 89 92
Data are means 6 SD or n.* P , 0.05. **P , 0.01 between groups. †HOMA-B = (20 x FPI [mIU/L])/(FPG [mmol/L]23.5) (calculated excluding FPG values # 3.5
mmol/L [formula invalid] and atypical insulin values [$249 pmol/L screening values substituted when baseline values unavailable]).
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population (Table 2). The positive effect
of TRT on the erectile function domain in
the ITT population (Table 2) approached
signiﬁcance in the mPP exploratory anal-
ysis (TD 3.225 [95% CI 20.454 to
6.904]; P =0 . 0 8 9 ) .
Safety: Phases 1 and 2
In the safety population, 137 patients
(62%) experienced 502 AEs with 224
(45%) considered to be related to study
medication (TRT, 116; placebo, 108).
The majority of AEs were classiﬁed as
mild or moderate (TRT, 98%; placebo,
97%) with no signiﬁcant differences be-
tweentreatments.ThemostcommonAEs
in patients experiencing $1A Ew e r e
erythema (TRT, 4%; placebo, 5%), pru-
ritis (TRT, 4%; placebo, 4%), and naso-
pharyngitis (TRT, 3%; placebo 4%)
(Supplementary Table A5).
A total of 17 serious AEs were expe-
rienced by 13 patients. Of these, 3 in the
placebo group were considered related to
treatment. Thirteen resolved without se-
quelae. One patient (placebo) died as the
result of myocardial infarction. A total of
30 patients withdrew from the study
because of AEs (TRT, 18; placebo, 12).
The most common AEs leading to dis-
continuationwereskinandsubcutaneous
tissuedisorders(21AEs;testosterone,11;
placebo, 10). Cardiovascular events oc-
curred more commonly with placebo
(10.7 vs. 4.6%; P = 0.095).
No clinically relevant mean changes
in laboratory parameters were noted.
After 12 months, hematocrit had in-
creased by 0.03 6 0.04 L/L for TRT
versus a decrease of 20.01 6 0.02 L/L
for placebo, and hemoglobin levels had
increased by 1.42 6 1.55 g/dL from base-
line (TRT) versus 0.06 6 0 . 7g / d L( p l a -
cebo).Therewasnosigniﬁcantincreasein
age-adjusted PSA values. The PSA level
exceeded the upper limit of age-adjusted
normalvaluesinthreesubjectsatbaseline
(testosterone, 2; placebo, 1). This viola-
tion of the entry criteria would not have
affected the primary efﬁcacy end point,
and because the patients had been ran-
domized and were satisfactorily proceed-
inginthestudytheywerenotwithdrawn.
None of these patients underwent pros-
tate biopsy during the study. PSA levels
exceeded normal limits in four subjects at
12 months (TRT, 3; placebo, 1).
CONCLUSIONS—Thisstudydemon-
strates thattransdermalTRTinhypogonadal
men with type 2 diabetes and/or MetS
improves IR, the central biochemical
defect associated with these conditions.
This result is of added interest, as many
study participants were already taking
OADs (mainly metformin), which affect
insulin sensitivity. Although an im-
provement in IR could be expected to
result in better glycemic control, no re-
duction in HbA1c was demonstrated af-
ter 6 months of treatment. Previous
studies have reported that TRT does im-
prove glycemic control (6,9); however,
the current study was not powered to
detect changes in glycemic control and
included patients with controlled dia-
betes (HbA1c ,6.5%). A signiﬁcant dif-
ference in HbA1c between the TRT
and placebo groups was observed at 9
months, but this potential treatment ef-
fect was confounded by the permitted
changes in diabetes-related medications
for ethical reasons. Therefore, no clear
conclusion can be made. A larger deﬁn-
itive study with HbA1c as a primary end
p o i n ti nh y p o g o n a d a lm e nw i t hu n c o n -
trolled diabetes is required to investigate
this further.
The majority of cross-sectional stud-
ies have shown that hypogonadism is
associated with dyslipidemia, albeit with
conﬂicting results (4). There are only lim-
ited data supporting the effect of testos-
terone gel formulations on lipids. Two
studies reported a small rise in HDL cho-
lesterol but no effect on TC or LDL cho-
lesterol in hypogonadal men (9,21). In
the current study, Lpa was signiﬁcantly
reduced compared with placebo in the
overall population after 6 months of ther-
apy. Moreover, the subgroup of patients
with MetS at baseline showed signiﬁcant
reductions frombaselinewith TRT versus
placebo, in Lpa, TC, and LDL cholesterol
after 6 months, even though the majority
of these patients were taking statins and
h a dm e a nb a s e l i n eT Cc o n c e n t r a t i o n s
below 5 mmol/L. A reduction in HDL
cholesterol has been reported in studies
using intramuscular testosterone ester
therapy (4).
Lpa is a strong independent risk
factor for premature coronary heart dis-
ease(22).Surgicalorchidectomyforpros-
tate cancer increases Lpa concentrations,
whereas administration of testosterone in
healthy men reduces Lpa levels (23). In
the current study, reductions from base-
line in serum Lpa concentration were sig-
niﬁcantly greater in TRT-treated patients
at month 6 in both the overall population
and the MetS subgroup. The long-term
cardiovascular beneﬁts of reducing Lpa
are unknown.
The safety and tolerability proﬁle of
TRT was comparable to placebo with no
signiﬁcant differences in cardiovascular
events,includingbloodpressure.Caution
has been urged following a recent study
that reported an increase in cardiovascu-
lar events in testosterone-treated, frail,
elderly men (24). However, cardiovascu-
lar events were not a planned outcome
in this study, and veriﬁcation of events
varied among subjects. Moreover, .70%
of the men in that trial received higher
doses of testosterone (100 or 150 mg/day)
than any of the men in the current study
(40280 mg/day). The current study
showed a trend for cardiovascular events
to occur more frequently in the placebo
group than in the TRT group. A similar
frailty study that used standard doses (tes-
tosterone gel 50 mg/day) in clinical prac-
tice found no increase in cardiovascular
events (25).
The frequency of application site re-
actions in this study was higher than has
been reported in other trials involving
transdermal TRT. However, in TIMES2
mandatory application site inspections
were performed at each study visit, and
the investigators were trained to identify
and document skin-related reactions.
This is in contrast to other studies that
relied on patients reporting a dermato-
logical AE.
The beneﬁcial effects of TRT on over-
all sexual function and, importantly, li-
bido (a key symptom of testosterone
deﬁciency) support the assessment and
treatment of hypogonadism in men with
type 2 diabetes and/or MetS who do not
present speciﬁcally with erectile dysfunc-
tion.
Results from the mPP population
should be regarded as exploratory only,
since this population was created as part
of a post hoc analysis. However, these
results have been included because they
allow assessment of the impact of testos-
terone on individual parameters without
the potential confounding inﬂuence of
changes in concomitant medication. Al-
though this information is typically
gained from the PP population, the small
size of the PP population here limited the
power of any analyses and precluded
analysis of disease subgroup data (MetS
and type 2 diabetes). The mPP data pro-
vide supportive evidence that TRT im-
proves glycemic control, lipid proﬁle,
central obesity and body composition in
hypogonadal men with type 2 diabetes
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of statistical signiﬁcance for some end
points between 6 and 12 months is likely
to be due to the smaller size of the
population at month 12 and the allowed
use of concomitant medications after 6
months (Supplementary Table A3). The
d e l a y e de f f e c to fT R To nH b A 1c could
be explained by the cumulative effect
on reduction in body fat over several
months.
The high dropout rate is a limitation
of this study. However, there was no
difference between treatment groups in
the number or characteristics of the pa-
tients who failed to complete the study.
This study has shown that TRT in
hypogonadal men with type 2 diabetes
and/or MetS improves several cardiovas-
cular risk factors, most notably IR, Lpa,
TC, and LDL cholesterol. These ﬁndings
and the therapeutic beneﬁto ns e x u a l
function strongly support a role for TRT
in these clinical conditions.
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